Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915734 | 0.95 | SMN1; SMN2 (0.31) | SMN1; SMN2HTTLMNARAB9AMEN1 | |
| SCHEMBL20658164 | 0.90 | TSHR (0.38) | SMN1; SMN2HTTLMNARAB9AMEN1 | |
| SCHEMBL20658212 | 0.78 | TSHR (0.33) | LMNAMEN1KMT2ATSHR | |
| SCHEMBL14915466 | 0.77 | TSHR (0.31) | SMN1; SMN2HTTLMNARAB9AMEN1 | |
| SCHEMBL14914778 | 0.77 | TSHR (0.31) | SMN1; SMN2HTTLMNARAB9AMEN1 | |
| SCHEMBL14914085 | 0.75 | CYP1A2 (0.32) | MAPT | |
| SCHEMBL2430231 | 0.74 | TSHR (0.43) | LMNATSHR | |
| Ethyne SCHEMBL9421962 | 0.74 | TSHR (0.40) | SMN1; SMN2LMNATSHR | |
| SCHEMBL135552 | 0.73 | TSHR (0.46) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL28438742 | 0.73 | TSHR (0.46) | SMN1; SMN2LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473476-B | Alkynyl heterocyclic compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10711075-B2 | Method of preparing rubber composition including syndiotactic 1,2-polybutadiene | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| US-20190023815-A1 | METHOD OF PREPARING RUBBER COMPOSITION INCLUDING SYNDIOTACTIC 1,2-POLYBUTADIENE | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2019-01-24 | — | — | US | disclosed |
| US-20130115520-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND ELECTROCHEMICAL ELEMENT UTILIZING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| EP-1966220-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INC. | 2004-08-05 | — | — | US | disclosed |
| EP-0334590-B1 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | LILLY CO ELI (US) | 2001-07-04 | — | — | EP | disclosed |
| US-5716906-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-10 | — | — | US | disclosed |
| US-5563263-A | EPOXIDATION CATALYSTS | HOECHST CELANESE CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| WO-1996008311-A1 | D4-SYMMETRIC PORPHYRIN-BASED CATALYSTS, PROCESSES FOR PREPARING SAME, AND PROCESSES FOR USING SAME | HOECHST CELANESE CORPORATION (US) | 1996-03-21 | — | — | WO | disclosed |
| EP-0677523-A1 | 3-(substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5227508-A | Antitumor | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1993-07-13 | — | — | US | disclosed |
| US-5128336-A | Antibiotics | ELI LILLY AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0334590-A2 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4855418-A | Process for production of ceophalosporins | ELI LILLY AND COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152717-A1 | 5-Substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds | PGR, FSHR, GPER1 | SMN1; SMN2 4857/4885HTT 4607/4885LMNA 3450/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | SMN1; SMN2 2240/4885HTT 2895/4885LMNA 444/4885 |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | SMN1; SMN2 653/4885HTT 374/4885LMNA 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.